| 2.54 -0.08 (-3.05%) | 02-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 9.98 | 1-year : | 14.76 |
| Resists | First : | 8.54 | Second : | 12.64 |
| Pivot price | 2.73  |
|||
| Supports | First : | 1.91 | Second : | 1.59 |
| MAs | MA(5) : | 2.43 |
MA(20) : | 2.9 |
| MA(100) : | 60.03 |
MA(250) : | 132.53 |
|
| MACD | MACD : | -4.4 |
Signal : | -5.8 |
| %K %D | K(14,3) : | 43.1 |
D(3) : | 33.9 |
| RSI | RSI(14): 21 |
|||
| 52-week | High : | 468.35 | Low : | 1.91 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PBM ] has closed above bottom band by 32.2%. Bollinger Bands are 97% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.64 - 2.65 | 2.65 - 2.67 |
| Low: | 2.4 - 2.41 | 2.41 - 2.42 |
| Close: | 2.6 - 2.62 | 2.62 - 2.64 |
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Mon, 23 Feb 2026
Psyence BioMed Announces Exercise Of Put Option By Psyence Labs; Stock Up - Nasdaq
Fri, 20 Feb 2026
Psychedelics partner PsyLabs to own 49.98% of Psyence BioMed - Stock Titan
Fri, 20 Feb 2026
Psyence Biomedical Ltd. Invests in Psyence Labs Ltd. to Enhance Strategic Relationship and Supply Chain Capabilities - Quiver Quantitative
Thu, 19 Feb 2026
Weiner discloses 51,850-share, 5.07% stake in Psyence Biomedical (PBM) - Stock Titan
Tue, 17 Feb 2026
Psilocybin developer’s investors back plan to combine shares up to 250-for-1 - Stock Titan
Tue, 17 Feb 2026
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 9.9 (%) |
| Held by Institutions | 2.7 (%) |
| Shares Short | 23 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -389.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 39.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -34.5 % |
| Return on Equity (ttm) | -74.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.07 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -4 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.06 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.61 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|